Dechra Pharmaceuticals PLC Appointment of John Shipsey as Non-Executive (7891L)

TIDMDPH

RNS Number : 7891L

Dechra Pharmaceuticals PLC

17 May 2022

17 May 2022

Dechra(R) Pharmaceuticals PLC

(Dechra, the Company or the Group)

Appointment of John Shipsey as Non-Executive Director

Dechra is pleased to announce that, with effect from 1 June 2022, John Shipsey will be appointed as a Non-Executive Director of the Company. John will be a member of the Group's Audit, Remuneration and Nomination Committees with the intention that he will be appointed as Chair of the Audit Committee upon Julian Heslop's retirement as Audit Committee Chairman on 1 September 2022.

John has valuable experience leading innovative, high growth companies and brings a wealth of financial and commercial experience to the business. In addition, his recent tenure as Chief Financial Officer at FTSE100 Smiths Group PLC (January 2018 to April 2022) will be a highly relevant asset to the Board and Dechra. Prior to this he was Chief Financial Officer for Dyson, the diversified global technology company where he was part of the team that led its international growth, particularly in Asia. His previous experience includes a number of senior finance and strategy roles over 13 years at Diageo plc, including Finance Director for its Iberia region and Chief Financial Officer of Schieffelin & Somerset, a US joint venture between Diageo and LVMH.

John is a Chartered Accountant and has an MBA from INSEAD.

There are no other disclosures to be made in respect of John Shipsey, pursuant to Listing Rule 9.6.13R.

 
Enquiries to: 
Dechra Pharmaceuticals PLC 
Ian Page, Chief Executive Officer 
Office: [phone] 
e-mail: [e-mail] 
 
TooleyStreet Communications Ltd 
Fiona Tooley, Director 
 Mobile: [phone] 
 e-mail: [e-mail] 
 

About Dechra

Dechra is a global specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.

For more information please visit: www.dechra.com

Stock Code: Full Listing (Pharmaceuticals): DPH

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOABDLFFLELBBBL

(END) Dow Jones Newswires

May 17, 2022 14:06 ET (18:06 GMT)